Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company developing innovative therapeutics using its proprietary bicyclic peptide (Bicycle®) technology, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, with a fireside chat at 8:30 a.m. ET
2. 2024 Cantor Global Healthcare Conference on September 18, with a fireside chat at 11:30 a.m. ET
Live webcasts of both fireside chats will be available on the company's website in the Investor section, with archived replays accessible after the events. This participation provides an opportunity for investors to gain insights into Bicycle Therapeutics' progress and future plans.
Bicycle Therapeutics (NASDAQ: BCYC), un'azienda farmaceutica che sviluppa terapie innovative utilizzando la propria tecnologia di peptide biciclico (Bicycle®), ha annunciato la sua partecipazione a due prossimi eventi per investitori nel settembre 2024:
1. 22° Conferenza Annuale Mondiale sulla Salute di Morgan Stanley il 4 settembre, con un incontro di approfondimento alle 8:30 a.m. ET
2. Conferenza Mondiale sulla Salute Cantor 2024 il 18 settembre, con un incontro di approfondimento alle 11:30 a.m. ET
I webcast dal vivo di entrambi gli incontri saranno disponibili sul sito web dell'azienda nella sezione dedicata agli investitori, con registrazioni archiviabili accessibili dopo gli eventi. Questa partecipazione offre un'opportunità agli investitori per avere informazioni sui progressi e sui piani futuri di Bicycle Therapeutics.
Bicycle Therapeutics (NASDAQ: BCYC), una empresa farmacéutica que desarrolla terapias innovadoras utilizando su tecnología de péptidos bicíclicos (Bicycle®), ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024:
1. 22ª Conferencia Anual Global de Salud de Morgan Stanley el 4 de septiembre, con una charla informal a las 8:30 a.m. ET
2. Conferencia Global de Salud Cantor 2024 el 18 de septiembre, con una charla informal a las 11:30 a.m. ET
Las transmisiones en vivo de ambas charlas estarán disponibles en el sitio web de la empresa en la sección de Inversores, con repeticiones archivas accesibles después de los eventos. Esta participación proporciona una oportunidad para que los inversores obtengan información sobre el progreso y los planes futuros de Bicycle Therapeutics.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 독자적인 이성질체 펩타이드(Bicycle®) 기술을 활용하여 혁신적인 치료법을 개발하는 제약회사로, 2024년 9월 열리는 두 가지 투자자 회의에 참가한다고 발표했습니다:
1. 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스가 9월 4일에 열리며, 오전 8:30(ET)에 대화가 진행됩니다.
2. 2024 칸토 글로벌 헬스케어 컨퍼런스가 9월 18일에 열리며, 오전 11:30(ET)에 대화가 진행됩니다.
두 번의 대화는 회사 웹사이트의 투자자 섹션에서 실시간으로 방송될 예정이며, 행사 후 아카이브 다시보기도 가능합니다. 이번 참가를 통해 투자자들은 바이시클 테라퓨틱스의 진행 상황과 향후 계획에 대한 통찰을 얻을 수 있는 기회를 가집니다.
Bicycle Therapeutics (NASDAQ: BCYC), une société pharmaceutique développant des thérapies innovantes grâce à sa technologie de peptides bicycliques (Bicycle®), a annoncé sa participation à deux conférences pour investisseurs prévues en septembre 2024 :
1. 22ème Conférence Annuelle Mondiale de la Santé de Morgan Stanley le 4 septembre, avec une discussion à 8h30 ET
2. Conférence Mondiale de la Santé Cantor 2024 le 18 septembre, avec une discussion à 11h30 ET
Des retransmissions en direct de ces deux discussions seront disponibles sur le site internet de l'entreprise dans la section Investisseurs, avec des rediffusions accessibles après les événements. Cette participation offre aux investisseurs une occasion d'obtenir des informations sur les progrès et les futurs projets de Bicycle Therapeutics.
Bicycle Therapeutics (NASDAQ: BCYC), ein Pharmaunternehmen, das innovative Therapien mit seiner proprietären bicyclischen Peptidtechnologie (Bicycle®) entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben:
1. 22. Jährliche Globale Gesundheitskonferenz von Morgan Stanley am 4. September, mit einem Gesprächsformat um 8:30 Uhr ET
2. 2024 Cantor Globale Gesundheitskonferenz am 18. September, mit einem Gesprächsformat um 11:30 Uhr ET
Live-Webcasts beider Gespräche werden auf der Website des Unternehmens im Investorenbereich verfügbar sein, mit archivierten Aufzeichnungen, die nach den Veranstaltungen zugänglich sind. Diese Teilnahme bietet Anlegern die Möglichkeit, Einblicke in die Fortschritte und zukünftigen Pläne von Bicycle Therapeutics zu gewinnen.
- None.
- None.
- Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4; fireside chat at 8:30 a.m. ET
- 2024 Cantor Global Healthcare Conference on Wednesday, Sept. 18; fireside chat at 11:30 a.m. ET
Live webcasts of the fireside chats will be accessible in the Investor section of the company’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following the fireside chat dates.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821442994/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Media:
Deborah Elson
Argot Partners
media@bicycletx.com
212-600-1902
Source: Bicycle Therapeutics plc
FAQ
When is Bicycle Therapeutics (BCYC) participating in the Morgan Stanley Global Healthcare Conference?
What is the date and time of Bicycle Therapeutics' (BCYC) fireside chat at the Cantor Global Healthcare Conference?
How can investors access the webcasts of Bicycle Therapeutics' (BCYC) investor conference presentations?
What type of technology does Bicycle Therapeutics (BCYC) specialize in?
